Abstract: A compound having an antiviral activity for inhibiting release of an enveloped virus from a cell is disclosed, including methods of inhibiting release of an enveloped virus from a cell. The antiviral activity of the compound includes inhibiting formation of an associative complex or disrupting formation of an associative complex. The associative complex comprises an L-domain motif of the enveloped virus and at least one cellular polypeptide, or fragment thereof, capable of binding the L-domain motif of the enveloped virus.
Type:
Grant
Filed:
November 10, 2015
Date of Patent:
May 28, 2019
Assignees:
Northwestern University, The Research Foundation for the State University
Abstract: Doxycycline formulations with a reduced food effect are disclosed. Particularly disclosed are modified release formulations which can be administered once a day and exhibit a reduced food effect. Methods of treating inflammatory conductions such as rosacea or inflammatory symptoms such as the papules and pustules of rosacea or acne vulgaris are also disclosed.
Abstract: Provided herein are methods for treating, preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.
Abstract: Use of oxymethylene aryl GPR119 agonists, and optionally DPP IV inhibitors and optionally metformin, for the treatment of inflammatory gastrointestinal diseases or gastrointestinal conditions involving malabsorption of nutrients and/or fluids are provided.
Abstract: The present disclosure is directed to alcohol-based anti-adherent compositions that do not adhere to or attract Gram-negative and Gram-positive bacteria once it is applied to a surface and dried. The composition may include as anti-adherent agents, hydrophilic film-formers such as cellulosics, gums, acrylates, nonionic polymers, and anionic polymers. Examples of anti-adherent agents include Hydroxypropyl methylcellulose, Cellulose gum, Acacia Senegal Gum; Polyacrylate Crosspolymer-11, VP/Dimethylaminoethylmethacrylate/Polycarbamyl Polyglycol Ester; Acrylates/Vinyl Neodecanoate Crosspolymer, hydroxypropyl methylcellulose, Hydroxypropylcellulose, Methylcellulose, Propylene Glycol Alginate, Polyacrylate Crosspolymer-6, VP/Polycarbamyl Polyglycol Ester, Acrylates/Steareth-20 Methacrylate Copolymer; Acrylates Copolymer, and any combination thereof. The anti-adherent may be applied to surfaces using a vehicle such as a wipe.
Type:
Grant
Filed:
June 18, 2018
Date of Patent:
May 21, 2019
Assignee:
Kimberly-Clark Worldwide, Inc.
Inventors:
Vinod Chaudhary, Scott W. Wenzel, Kathleen C. Engelbrecht, David W. Koenig, Amy L. Vanden Heuvel, Divesh Bhatt, Paige N. Hollmaier (Anunson), Stacy A. Mundschau
Abstract: Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.
Type:
Grant
Filed:
March 19, 2018
Date of Patent:
May 14, 2019
Assignee:
Samumed, LLC
Inventors:
Sunil Kumar KC, Gopi Kumar Mittapalli, Brian Joseph Hofilena, Joseph Timothy Marakovits, Chandramouli Chiruta, Chi Ching Mak, Jianguo Cao
Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.
Type:
Grant
Filed:
November 21, 2017
Date of Patent:
May 7, 2019
Assignee:
OTSUKA AMERICA PHARMACEUTICAL, INC.
Inventors:
Anthony Alexander McKinney, Franklin Bymaster, Walter Piskorski, Fred J. Fleitz, Yonglai Yang, David A. Engers, Valeriya Smolenskaya, Venkat Kusukuntla
Abstract: Subject of the present invention are biomarkers and methods for the identification of an increased risk of the progression of chronic kidney disease (CKD), or for monitoring chronic kidney disease therapy, comprising the detecting the level of one or more of NTpro BNP, EGF, Apo H, GDF-15, and albumin-to-creatinine ratio.
Type:
Grant
Filed:
October 31, 2014
Date of Patent:
April 30, 2019
Assignee:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Inventors:
Maria Bobadilla, Laura Badi, Guillemette Duchateau-Nguyen, Laurent Essioux, Hanno Langen, Maria Chiara Magnone, Thomas Schindler, Martina Thier, Ivan Formentini, Gonzalo Christian Duran Pacheco, Corinne Solier, Matthias Kretzler, Viji Nair, Ju Wenju
Abstract: The present invention relates to methods of treating or preventing arthropod infestations of poultry animals and methods of controlling arthropod infestations in poultry animal's environment by administering an isoxazoline compound of formula (I) via drinking water.
Type:
Grant
Filed:
December 19, 2014
Date of Patent:
April 30, 2019
Assignee:
Intervet Inc.
Inventors:
Anja Regina Heckeroth, Hartmut Zoller, Annie Flochlay-Sigognault, Bruno Huyghe
Abstract: Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.
Type:
Grant
Filed:
September 18, 2017
Date of Patent:
April 30, 2019
Assignees:
The Regents of the University of California, Meritage Pharma, Inc.
Inventors:
Ranjan Dohil, John Bastian, Seema Aceves, Elaine Phillips, Malcolm Hill
Abstract: A method of treating steroid-dependent disease such as prostate cancer in a subject is described that includes administering a therapeutically effective amount a CYP17A inhibitor and an effective amount of a 5-?-reductase inhibitor to the subject.
Type:
Grant
Filed:
March 7, 2016
Date of Patent:
April 23, 2019
Assignees:
THE CLEVELAND CLINIC FOUNDATION, THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Inventors:
Nima Sharifi, Zhenfei Li, Richard Auchus
Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as osteoarthritis.
Abstract: A composition suitable for topical application comprising a continuous phase and at least one discontinuous phase, said composition comprising at least one polyaphron dispersion, at least one vitamin D or vitamin D analog and at least one corticosteroid.
Type:
Grant
Filed:
March 14, 2008
Date of Patent:
April 23, 2019
Assignee:
DRUG DELIVERY SOLUTIONS LIMITED
Inventors:
Derek Wheeler, David F. Steele, Michelle Georgiou, Steen Sindet-Pedersen
Abstract: The present invention relates to cannabinoids for use in the prevention or treatment of neurodegenerative diseases or disorders. Preferably the cannabinoids are cannabichromene (CBC) cannabidivarin (CBDV) and/or cannabidivarin acid (CBDVA). More preferably the neurodegenerative disease or disorder to be prevented or treated is Alzheimer's disease.
Type:
Grant
Filed:
June 29, 2012
Date of Patent:
April 16, 2019
Assignee:
GW Pharma Limited
Inventors:
Teresa Iuvone, Vincenzo Di Marzo, Geoffrey Guy, Stephen Wright, Colin Stott
Abstract: Disclosed herein are formulations containing carbidopa and optionally levodopa, arginine, and other components that have reduced levels of impurities and toxins, particularly degradation productions. Also disclosed herein are methods of treatment diseases or conditions relating to a loss of dopamine or dopaminergic neurons using such formulations, methods of making such formulations, and kits that include such formulations.
Abstract: Provided herein, inter alia, are methods for the preparation of modulators of farnesoid X receptor (FXR), and compositions and uses of the modulators of FXR.
Abstract: Described herein are fungicidal compositions in the form of an emulsifiable concentrates that include a first fungicidal compound, optionally, at least one additional fungicidal compound, two or more surfactants and a water immiscible organic solvent comprised of a mixture of organic compounds including at least one acetate ester and at least one N,N-dialkylcarboxamide. The compositions are homogeneous, stable upon storage, and upon dilution in water form stable emulsions that can be sprayed onto plants to control important fungal diseases.
Type:
Grant
Filed:
February 21, 2018
Date of Patent:
March 26, 2019
Assignee:
Dow AgroSciences LLC
Inventors:
Derek J. Hopkins, Cheryl Ann Cathie, Todd Mathieson, Neil A. Foster
Abstract: Compositions including a fatty acid, such as an odd chain fatty acid or a very long even chain fatty acid, and salts and derivatives thereof, and methods for treatment and prophylaxis of conditions related to anemic conditions, are provided, including compositions and methods for treating anemic conditions such as hemolytic anemia and anemia of chronic disease, and other related conditions.
Type:
Grant
Filed:
December 29, 2016
Date of Patent:
March 26, 2019
Assignee:
The United States of America as represented by the Secretary of the Navy
Abstract: This invention provides a high molecular weight polysaccharide capable of binding to and inhibiting virus and related pharmaceutical formulations and methods of inhibiting viral infectivity and/or pathogenicity, as well as immunogenic compositions. The invention further includes methods of inhibiting the growth of cancer cells and of ameliorating a symptom of aging. Additionally, the invention provides methods of detecting and/or quantifying and/or isolating viruses.
Type:
Grant
Filed:
June 14, 2017
Date of Patent:
March 19, 2019
Assignee:
WORLD FORCE TECHNOLOGIES, LLC
Inventors:
Thomas W. Konowalchuk, Jack Konowalchuk
Abstract: The disclosure relates to a pharmaceutical combination of a mdm2/4 inhibitor, namely (S)-1-(4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one or (S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one, and a cyclin dependent kinase 4/6 (CDK4/6) inhibitor 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide. In addition, the disclosure relates to a pharmaceutical combination product. The disclosure also relates to corresponding pharmaceutical formulations, uses and treatment methods comprising said mdm2/4 inhibitor or a cyclin dependent kinase 4/6 (CDK4/6) inhibitor.